Interface Biologics (IBI), a developer of biomedical-polymer products, has entered into a license agreement with Navilyst Medical.
As per the agreement, Navilyst has gained exclusive rights to integrate IBI’s Endexo technology in its vascular access products.
Endexo is a self-locating bio-medical polymer additive that reduce the chemical reactivity on the surface incuding platelet adhesion, protein adsorption and thrombus formation on medical devices, thus enhancing biocompatability.
Navilyst Medical has introduced BioFloPICCs with Endexo Technology, following Canadian approval in August.